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Diabetic nephropathy (DN) not only is a major cause of end-stage renal disease (ESRD) in developing and
developed countries but also plays a critical role as a risk factor for cardiovascular disease. The pathogenesis of DN
is multifactorial and remains to be elucidated. It is well known that dyslipidemia is frequently complicated with
diabetes. Recently, dyslipidemia has been recognized to be involved in the progression of DN. In general, diabetic
dyslipidemia is caused by impaired action of lipoprotein lipase (LPL) that is localized to the endothelial cells,
resulting in increased serum levels of increased triglyceride (TG) and decreased high-density lipoprotein cholesterol
(HDL-C). Smaller size and modified low-density lipoprotein (LDL), such as glycated and oxidized LDL, play important
roles to induce vascular and renal cellular dysfunction. Previous studies demonstrated that dyslipidemia enhances
macrophage infiltration and excessive extracellular matrix (ECM) production in the glomeruli under diabetic
conditions, leading to the development of DN. Clinical studies have demonstrated that lipid-lowering therapy
shows a protective effect on the renal function. It is well known that statins reduce albuminuria in patients with
DN. A series of our studies indicated that this effect is mediated by Rho-kinase inhibition. Rho-kinase plays a key
role in the pathogenesis of DN by activating the inflammatory pathway, including oxidative stress, NF-κB, and
hypoxia inducible factor (HIF)-1. Intriguingly, Rho-kinase inhibitors have been shown to attenuate glomerulosclerosis
as well as atherosclerosis. Therefore, Rho-kinase could be a promising therapeutic target for both DN and
cardiovascular disease.
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Dyslipidemia, an important risk factor for cardiovascular
disease, is frequently complicated with diabetic nephrop-
athy (DN). Managing dyslipidemia in DN is extremely
important because patients with DN are at a high risk
for cardiovascular disease-associated death [1]. Further-
more, dyslipidemia has been shown to play crucial roles
in the development and progression of DN [2]. Impaired
lipoprotein metabolism, such as increases in very low
density lipoprotein (VLDL-C) and low-density lipopro-
tein cholesterol (LDL-C) and a decrease in high-density
lipoprotein cholesterol (HDL-C), is observed in patients
with diabetes [3]. In addition to these quantitative
changes, quality changes including small dense LDL [4]
and oxidized LDL (ox-LDL) make lipoproteins more
proatherogenic in diabetes. This review article describes
our current understanding of the role of dyslipidemia in* Correspondence: daijika@jikei.ac.jp
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disease and DN.Etiology and epidemiology of diabetic
dyslipidemia
Typically, patients with type 2 diabetes show increased
serum levels of triglyceride (TG) and decreased HDL-C.
Furthermore, modifications of LDL, such as glycation
and oxidation, are enhanced under diabetic conditions.
The prevalence of high LDL-C in patients with diabetes
appears to be similar to that of the general population,
as demonstrated by the Framingham Study and the
United States National Health and Nutritional Examin-
ation Survey (NHANES) [5]. In the United Kingdom
Prospective Diabetes Study (UKPDS), no differences in
total cholesterol levels were reported between diabetic
and non-diabetic subjects. The LDL-C levels were com-
parable in males but higher in females with type 2 dia-
betes compared to those without type 2 diabetes [6]. On
the other hand, increased serum levels of TG andicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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these studies. In the Framingham Study, an elevation in
serum was observed in 19 % of males and 17 % of fe-
males with type 2 diabetes, whereas it was observed in
9 % of males and 8 % of females in non-diabetic subjects
[7]. In the UKPDS, 50 % of patients with type 2 diabetes
had high serum levels of TG [6]. The Heart Protection
Study (HPS) showed that the prevalence of low HDL-C
was higher in diabetic individuals (21 % in males and
25 % in females) compared to non-diabetic individuals
(12 % in males and 10 % in females) [8].
Lipid metabolism in diabetes and DN
As described above, dyslipidemia in diabetes is charac-
terized by an increase in VLDL, LDL, and TG and a de-
crease in HDL [9]. Under the diabetic milieu, hormone-
sensitive lipase is activated, which results in the release
of free fatty acid (FFA) from the adipose tissue. The flux
of FFA promotes hepatic triglyceride production, leading
to excessive apoB and VLDL synthesis [9]. In addition,
lipoprotein lipase (LPL) activity is suppressed under the
condition of insulin resistance [10]. These changes result
in an increase in the serum levels of TG and remnant
particles. Apolipoprotein (apo) B48, a major component
of chylomicron, is also increased in diabetes, suggesting
an accumulation of chylomicron remnants [11]. It has
been demonstrated that insulin resistance is aggravated
along with the progression of DN, even in the early stage
of microalbuminuria [12]. An elevation in the serum
levels of apoC-III, an inhibitor of LPL, is also observed
in subjects with DN [3].
It has been reported that the serum level of apoB100
is increased in DN [13]. ApoB100 is synthesized in the
liver and transferred into VLDL or LDL particles at one
molecule per particle. Therefore, a high serum level of
apoB100 indicates an increment in the number of VLDL
and LDL particles.
Cholesteryl ester transfer protein (CETP) mediates ex-
change of cholesteryl ester and TG. CETP activity is reg-
ulated by apoC-I, a physiological CETP inhibitor.
Recently, Bouillet et al. demonstrated that apoC-I’s abil-
ity to inhibit CETP activity is impaired in diabetic pa-
tients [14], which is explained by glycation of apoC-I
[14]. Furthermore, it has been shown that the CETP
levels are increased in ESRD patients, although the
precise mechanism remains unknown [15, 16]. VLDL
receives cholesteryl ester from HDL and transfers TG to
HDL by CETP. As a consequence, the amount of
cholesterol-rich VLDL remnant particles and cholesterol-
depleted HDL particles are increased. TG-rich HDL can
be hydrolyzed by LPL or hepatic TG lipase (HTGL),
thereby becoming lipid-poor HDL which is filtered by
the glomeruli and degraded in renal tubular cells [4]. In-
sulin has been shown to play an important role in theproduction of apoA-I, which is a major apolipoprotein
of HDL [17, 18]. As such, reduced insulin action is po-
tentially involved in the low HDL levels in type 2 dia-
betes, especially complicated with DN. Furthermore,
inflammatory cytokines including tumor necrosis factor
(TNF)-α have been shown to inhibit the production of
apoA-I and HDL [17]. Nevertheless, the mechanism
underlying low HDL in diabetes is complicated and re-
mains unclear.
Ox-LDL is a well-known atherogenic lipoprotein that
is modified by oxidation [4]. Recently, small dense LDL
is recognized as another important atherogenic lipopro-
tein due to its potent oxidative property. The serum
level of small dense LDL is increased in insulin resist-
ance and diabetes [3]. Of note, the serum level of small
dense LDL is reportedly elevated in patients with DN
[3], which may be associated with an increased risk for
cardiovascular disease in DN.
Impairment of the renal function by lipids
It has been recognized that lipid nephrotoxicity is in-
volved in the development of DN since the 1970s [19].
Previous studies have shown that dyslipidemia facilitates
glomerulosclerosis under diabetic conditions. Dyslipid-
emia complicated with diabetes has been shown to be
involved in the development of DN. We have previously
demonstrated that hypercholesterolemia exaggerates al-
buminuria in diabetic rats [20]. From a mechanistic
standpoint, this was the first report to demonstrate the
involvement of macrophage infiltration into the glom-
eruli in the progression of DN [20]. Furthermore, exces-
sive extracellular matrix (ECM) production was found in
the glomeruli of diabetic LDL receptor-deficient mice
[21]. Finally, lipid-lowering therapy has been shown to
improve glomerulosclerosis in the Zucker rat, a model
of diabetes complicated with dyslipidemia [22]. Mesan-
gial cells and glomerular epithelial cells (podocytes) have
been shown to express receptors for TG-rich lipopro-
teins (TGRLs) [23–26]. TGRLs stimulate inflammatory
pathways via the secretion of proinflammatory cytokines
such as TNF-α, transforming growth factor (TGF)-β,
and interleukin (IL)-6 [27], which results in the produc-
tion of reactive oxygen species (ROS), leading to exces-
sive ECM production. It has also been reported that
ROS itself potentiates TGF-β-mediated signaling, which
may cause a vicious cycle in the process of excessive
ROS and ECM production [2, 28]. Ox-LDL binds to
scavenger receptors in mesangial cells and podocytes
[29, 30], thereby increasing ECM production as well as
chemokine production, such as monocyte chemoattract-
ant protein (MCP)-1 which induces monocyte migration
toward the glomeruli and results in macrophage infiltra-
tion [31]. Macrophages become foam cells through the
uptake of ox-LDL and facilitate the inflammatory pathway.
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binding protein (SREBP)-1 and Toll-like receptor (TLR)
4, have been shown to mediate lipid nephrotoxicity
[32, 33]. The expression of SREBP-1, an important
regulator of cellular lipid synthesis [34], is upregulated
in STZ-induced diabetic rats. Interestingly, the pro-
gression of DN is inhibited in SREBP-1-deficient mice.
The development of DN is also inhibited in TLR4-
deficient mice fed a high-fat diet [32, 33].
Another mechanism by which TGRLs induce glomeru-
losclerosis is disruption of the endothelial cell glycocalyx
[2]. The glycocalyx is composed of proteoglycans, glyco-
proteins and glycosaminoglycans and located at the
interface between the lumen and endothelial surface
[35]. The glycocalyx maintains the endothelial function
and regulates glomerular permeability depending on the
size and charge of the solute [2]. It has been reported
that the volume of systemic glycocalyx was significantly
lower in patients with type 1 diabetes than in age-
matched control individuals [36]. More interestingly, pa-
tients with microalbuminuria showed lower volumes of
systemic glycocalyx compared to those without microal-
buminuria [36], suggesting that disruption of the glyco-
calyx may cause alterations in glomerular permeability,
leading to albuminuria.
Glycation of LDL has been shown to be involved in
the development of DN. Glycated LDL is a modified














Fig. 1 Role of dyslipidemia in diabetic nephropathy. Dyslipidemia promote
metabolism is accelerated in diabetic nephropathy that causes further renaglucose to LDL. Advanced glycation end-products
(AGEs) and receptor for AGEs (RAGE) are considered
to play critical roles in the pathogenesis of diabetic vas-
cular complications [37]. RAGE recognizes multiple
AGE-moieties as ligands including glycated LDL, thereby
inducing inflammatory and fibrotic responses [38].
Taken together, abnormal changes in the quantity and
quality of lipoproteins occur in DN, which in turn coor-
dinately promote impairment of the renal function in
diabetes (Fig. 1).
Significance of lipid-lowering therapy in DN
Statins and Rho-kinase
A significant body of evidence has shown the efficacy
and usefulness of statins in the management of DN
through its pleiotropic effects beyond lipid-lowering ef-
fects [39, 40]. Our previous study was the first report to
demonstrate a favorable effect of statins on the reduc-
tion of albuminuria in patients with type 2 diabetes [41].
Several studies including the Greek Atorvastatin and
Coronary Heart Disease Evaluation (GREACE) [42] and
Pravastatin Pooling Project [43] demonstrated that sta-
tins may be effective for maintaining the eGFR in pa-
tients with type 2 diabetes. In the Treating to New
Target (TNT) study, atorvastatin increased the eGFR in
patients with chronic kidney disease (CKD) [44]. Intri-
guingly, the Collaborative Atorvastatin Diabetes Study
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minuria [45]. Thus far, many groups have focused on the
mechanism whereby statins exhibit the renal protective
effect.
It is known that statins downregulate small GTP-
binding proteins and their downstream signaling path-
ways, including Rho/Rho-kinase activity [46]. The small
GTP-binding protein Rho and its effector, Rho-
associated kinase (Rho-kinase), have been implicated as
regulators of cell shape changes by rearrangements of
the actin cytoskeleton [47]. Rho cycles between an in-
active GDP-bound form and an active GTP-bound form
in response to various stimuli. GTP-bound Rho activates
its effector proteins (e.g., Rho-kinase) to initiate a down-
stream response [48–50] (Fig. 2). To bind GTP, Rho ne-
cessarily undergoes isoprenylation (geranylgeranylation),
which enables Rho to anchor into the plasma membrane
with a hydrophilic property. Statins inhibit the synthesis
of isoprenoids (geranylgeranyl pyrophosphate and farne-
syl pyrophosphate), intermediates of the cholesterol syn-
thetic pathway, which results in the suppression of Rho
activity (Fig. 3). Hence, we hypothesized that Rho/Rho-
kinase may be involved in the development of DN. We
found that Rho/Rho-kinase activity is increased in the
renal cortex of streptozotocin (STZ)-induced diabetic
rats. Interestingly, fasudil, a specific Rho-kinase inhibitor,
and fluvastatin ameliorated urinary excretion of albumin
concomitantly with a reduction in urinary excretion of
8-hydroxy-2′-deoxyguanosine (8-OHdG), an oxidative
stress marker [51], suggesting that fasudil improves DN
through the reduction of oxidative stress. Indeed, the ex-
pression of NOX4 messenger RNA (mRNA), a catalytic





Fig. 2 Rho/Rho-kinase. The small GTP-binding protein, Rho, and its downst
in various cellular functions. Under diabetic conditions, the Rho/Rho-kinase pa
response (e.g., NF-κB, HIF-1) are regulated by Rho/Rho-kinaserenal cortex of diabetic rats treated with fasudil. An add-
itional mechanistic analysis revealed that the expression
of TGF-β and connective tissue growth factor (CTGF) in
the renal cortex of diabetic rats was attenuated with fas-
udil treatment [51]. These findings indicate that the
Rho/Rho-kinase pathway plays a key role in the develop-
ment of DN. We further investigated the effect of Rho-
kinase inhibition on hypoxia inducible factor (HIF)-1α, a
transcriptional factor which has been implicated in the
pathogenesis of DN [52]. Although HIF-1α was shown
to be upregulated in the renal cortex of diabetic mice
(db/db mice), Rho-kinase blockade attenuates HIF-1α
induction and the subsequent fibrotic response under
diabetic conditions [53]. It was also suggested that this
change in HIF-1α was partly due to the regulation of
proteasomal degradation of HIF-1α by Rho-kinase [53].
We next elucidated the role played by the Rho/Rho-
kinase pathway in macrophage infiltration into the glom-
eruli. TNF-α, a potent inflammatory cytokine which is
involved in insulin resistance, induced the activation of
Rho/Rho-kinase and the expression of MCP-1 in cul-
tured mesangial cells. Y-27632, a specific inhibitor of
Rho-kinase, attenuated TNF-α-induced MCP-1 expres-
sion, indicating that TNF-α stimulates MCP-1 produc-
tion via a Rho/Rho-kinase-dependent pathway. This was
also confirmed by a chemotaxis assay demonstrating that
monocytic migration toward mesangial cells was sup-
pressed by a Rho-kinase inhibitor [54]. The expression
of macrophage colony-stimulating factor (M-CSF), an-
other important chemotactic cytokine, was also induced
by TNF-α via activation of Rho-kinase in cultured
mesangial cells [55]. Small interfering RNA-mediated
knockdown of ROCK1 and ROCK2, two isoforms ofG protein-coupled receptor






ream effector, Rho-associated kinase (Rho-kinase (ROCK)), are involved
thway is activated. Transcription factors that are involved in inflammatory
Fig. 3 Inhibition of Rho/Rho-kinase by statins. The pleiotropic effect of statins is exerted by Rho-kinase inhibition. Statins inhibit the production of
isoprenoids, which are important for Rho activation. Rho-kinase inhibitors specifically inhibit Rho-kinase function, thereby strongly attenuating
diabetic complications. GGPP geranylgreanyl pyrophosphate, GEF guanine nucleotide exchange factors
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able contribution to the M-CSF expression in mesangial
cells. Nuclear translocation and subsequent DNA bind-
ing of NF-κB RelA/p65 to the promotor site are critical
steps for the transcriptional regulation of M-CSF. We
found that TNF-α enhances nuclear translocation of
RelA/p65 in cultured mesangial cells. Interestingly, Rho-
kinase inhibitor suppressed nuclear translocation of
RelA/p65 and accordingly reduced the promoter activity
of the NF-κB binding site [55]. This study provided new
insight on the role of Rho-kinase, demonstrating that
Rho-kinase may regulate intracellular translocation of
transcriptional factors, likely through re-organization of
actin stress fibers. Finally, we have shown that Rho-
kinase blockade attenuates other microvascular compli-
cations such as diabetic retinopathy [56] and neuropathy
[57], as well as atherosclerosis [58]. Importantly, the ef-
fect of Rho-kinase inhibitors on diabetic complications
is independent of glucose and blood pressure [51, 53].
These findings suggest that Rho-kinase could be a com-
prehensive therapeutic target that governs both micro-
vascular and macrovascular complications.
A previous study showed that Rho-kinase inhibition
attenuates dyslipidemia-mediated CKD [59]. The study
investigated the effects of fasudil on spontaneously hy-
percholesterolemic (SHC) rats, an animal model of
CKD. The rats developed proteinuria accompanied by
Rho-kinase activation in the renal cortex. Intriguingly,
fasudil significantly attenuated proteinuria in SHC rats.Furthermore, the combination of fasudil and olmesar-
tarn exaggerated this effect [59]. A mechanistic analysis
revealed that fasudil inhibited the infiltration of macro-
phages into the glomeruli and podocyte injury, thereby
exerting protective effects against dyslipidemia-mediated
CKD [59]. It will be interesting to elucidate the relation-
ship between Rho-kinase and dyslipidemia in DN in the
future.
Fibrates
The mechanism by which fibrates ameliorate hypertri-
glyceridemia remains unknown; however, PPARα agonis-
tic property is considered to play a role in the effects of
fibrates. PPARα is expressed in the kidney and reported
to possess a renal protective effect in a lipid-lowering-
independent manner. The Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) study demonstrated
that fenofibrate suppresses the development and pro-
gression of DN [60]. Furthermore, the FIELD study re-
vealed that long-term administration of fenofibrate
retains the eGFR decline rate [61]. The Action to Con-
trol Cardiovascular Risk in Diabetes (ACCORD)-Lipid
study investigated the effect of combination therapy with
simvastatin and fenofibrate [62]. Compared to the con-
trol group (simvastatin alone), the combination therapy
group (simvastatin plus fenofibrate) significantly sup-
pressed the development of both microalbuminuria and
overt proteinuria in patients with type 2 diabetes [62]. In
this study, 47.4 % of the type 2 diabetic participants
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baseline after the initiation of fenofibrate therapy. How-
ever, this increase was reversible and there was no re-
sidual loss of eGFR over 5 years [63]. On the other
hand, 24.6 % of the participants had no increase in
serum creatinine levels [63]. Of note, the participants
with no increase in serum creatinine levels after the ini-
tiation of fenofibrate therapy appeared to have a lower
degree of renal function loss over 5 years of therapy in
comparison to the patients who received a placebo [63].
Taken together, these results indicate that fenofibrate
has protective effects against DN. However, it has been
reported that serum creatine levels are increased or un-
changed after fenofibrate treatment [64–66]. Although
fenofibrate treatment has been reported to alter the
renal hemodynamics [67] and induce the secretion of
creatinine from the renal tubules [68], the precise mech-
anisms by which fenofibrate increases the serum creatin-
ine levels are not fully understood.
Interestingly, bezafibrate has been shown to improve
glucose metabolism in diabetic individuals [69]. In this
study, dyslipidemic patients with diabetes were adminis-
tered bezafibrate along with anti-diabetic agents. A 24-
week administration of bezafibrate resulted in a signifi-
cant reduction in the HbA1c levels [69]. In relation to
enhancement of β-oxidation of fatty acid by bezafibrate,
two potential mechanisms have been raised according to
these observations. First, bezafibrate improves fatty acid
accumulation in β cells, thereby improving insulin secre-
tion. Second, fat accumulation in the liver and muscles
are reduced by bezafibrate [69, 70]. Such effect of
fibrates regarding the improvement in lipotoxicity and
insulin resistance may be beneficial for DN.
Ezetimibe
Ezetimibe is an inhibitor of a cholesterol transporter in
the small intestine (NPC1L1). The Study of Heart and
Renal Protection (SHARP) investigated the efficacy and
safety of ezetimibe in 9270 patients with CKD (including
3203 patients on dialysis) [71]. In this study, the patients
were randomized into the control and simvastatin-
ezetimibe combination therapy groups. A significant re-
duction in LDL-C was observed in the simvastatin-
ezetimibe group. Simvastatin-ezetimibe combination
therapy also reduced atherosclerosis-related events by
17 % in comparison to patients who received a placebo.
The combination of ezetimibe and simvastatin did not
worsen the renal function [71]. SHARP is the first study
to demonstrate that combination of a statin and ezeti-
mibe is effective in preventing atherosclerosis-associated
vascular events without adverse effect on the kidney in
patients with CKD. In SHARP, the effects of simvastatin-
ezetimibe combination therapy on CKD progression in
6245 non-dialyzed CKD patients were also analyzed[72]. More than 60 % of the patients in the study had ad-
vanced CKD (eGFR of <30 ml/min/1.73 m2) and 15 % of
patients had DN [72]. Simvastatin-ezetimibe combin-
ation therapy was not associated with a significant
change in the incidence of ESRD, while it doubled the
baseline creatinine level and led to a decline in the eGFR
rate in comparison to patients who received a placebo
[72]. These findings indicate that in CKD patients, ther-
apy to lower LDL-C prevents atherosclerotic disease but
not the progression of renal disease. To date, SHARP is
the largest trial to examine the effects of lipid-lowering
therapy in patients with advanced CKD. Further studies
will be required to elucidate whether lipid-lowering ther-
apy has preventive effects against the progression of
early stage DN. SHARP provided evidence that CKD pa-
tients should be indicated for lipid-lowering therapy to
prevent atherosclerotic events, regardless of their stage
of CKD.
PUFAs
The long-chain polyunsaturated fatty acids (PUFAs) con-
sist of omega-6 PUFAs (e.g., arachidonic acid (AA)) and
omega-3 PUFAs (e.g., eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA)). Omega-6 PUFAs are
absorbed through the consumption of plant oils such as
canola, which is rich in linoleic acid, and omega-3
PUFAs (EPA and DHA) are absorbed through fish con-
sumption. Among them, fish-oil-derived long-chain
omega-3 PUFAs have been shown to attenuate glomeru-
losclerosis and albuminuria in several investigations on
experimental DN [73–75]. Hasegawa et al. reported that
an intraperitoneal infusion of ethyl-EPA significantly de-
creased albuminuria along with inhibition of glomerulo-
sclerosis in KKAy/Ta mice, a model of type 2 diabetes
[73]. A mechanistic analysis showed that these observa-
tions were mediated by the anti-inflammatory and anti-
oxidative stress effects of EPA [74].
A retrospective analysis from the Diabetes Control and
Complications Trial (DCCT) revealed that the dietary
intake of long-chain omega-3 PUFAs is inversely associ-
ated with the degree, but not with the incidence, of albu-
minuria in type 1 diabetes [76]. A cross-sectional
analysis investigating the association between fish con-
sumption and microalbuminuria with or without dia-
betes has been performed [77]. It demonstrated that no
significant association was detected between fish con-
sumption and the incidence of microalbuminuria in pa-
tients with or without diabetes, but importantly, diabetic
patients that consumed more than two portions of fish a
week showed a lower risk for macroalbuminuria than
those who consumed less than one portion a week [77].
These epidemiologic studies suggest the potential favor-
able effect of long-chain omega-3 PUFAs on DN. How-
ever, clinical interventional studies investigating the
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Two studies which investigated the effect of long-chain
omega-3 PUFAs supplementation on albuminuria in pa-
tients with type 1 diabetes failed to show a significant re-
duction in albuminuria [78, 79]. In contrast, EPA
supplementation resulted in a significant reduction in
albuminuria in Japanese patients with type 1 and type 2
diabetes [80, 81]. Racial disparities may be involved in
these discrepancies, as it has been suggested that the
response to long-chain omega-3 fatty acid or fish con-
sumption may differ between Western and Asian popu-
lations [82]. Taken together, further clinical studies are
required to determine the effect of PUFA consumption
and supplementations on DN.
End-stage renal failure and lipid-lowering therapy
The effect of lipid-lowering therapy on the prevention of
cardiovascular events has been established in patients
with moderate CKD. A meta-analysis indicated that the
effectiveness of statins is independent of moderate impair-
ment of the eGFR [83]. In contrast, evidence is lacking re-
garding the usefulness of statins in ESRD. The Deutsche
Diabetes Dialyse Studie (4D; the German Diabetes Dialysis
Study) investigated whether atorvastatin may affect car-
diovascular events in type 2 diabetic patients on
hemodialysis [84]. After a 4-year follow-up, atorvastatin
reduced the LDL-C level by approximately 40 % but failed
to improve cardiovascular events [84]. The AURORA trial
(A Study to Evaluate the Use of Rosuvastatin in Subjects
on Regular Hemodialysis: An Assessment of Survival and
Cardiovascular Events) obtained similar results [85]. Rosu-
vastatin significantly reduced the LDL-C levels, but it was
not able to inhibit cardiovascular events [85]. However, a
sub-analysis of the AURORA trial demonstrated that
rosuvastatin reduced cardiovascular events (32 % reduc-
tion compared to control) in patients with diabetes on
hemodialysis [86]. On the other hand, statin therapy failed
to show secondary prevention of cardiovascular events in
the Swedish Web-system for Enhancement and Develop-
ment of Evidence-based care in Heart disease Evaluated
According to Recommended Therapies (SWEDEHEART)
study [87]. In this study, statin therapy was initiated at dis-
charge to patients who were hospitalized due to new-
onset myocardial infarction. During a 1-year follow-up,
statin use significantly inhibited cardiac death in patients
with an eGFR (ml/min/1.73 m2) of 15 and over. Statin use
at discharge was associated with an improved 1-year sur-
vival of patients with mild-to-severe renal insufficiency.
However, this effect was attenuated in patients with ESRD
[87]. Taken together, evidence has not yet been established
for statin use in preventing cardiovascular disease in
ESRD patients. Further studies are required to investigate
whether the presence of diabetes affects the effectiveness
of statin use in ESRD.Conclusions
Dyslipidemia is an important therapeutic target in the
treatment of diabetes. Furthermore, DN accelerates abnor-
mal lipoprotein metabolism, which causes the progression
of DN as well as cardiovascular disease. Statin use should
be considered for patients with DN to prevent cardiovas-
cular events and renal impairment. However, further
evidence is required to establish the benefits of statin
use in patients with ESRD.
There is growing evidence that Rho-kinase plays a key
role in the development and progression of DN. Statins
inhibit Rho-kinase activation, which may be responsible
for the pleiotropic effects of statins. Our recent findings
raise the possibility that the use of Rho-kinase inhibitors
along with statins provides a more potent and specific
protective effect on DN.
Lipid-lowering therapy other than statins, such as
fibrate, is also important. However, it should be noted
that the combination of statin and fibrate is contraindicated
for patients with moderate to severe renal impairment.
The clinical background of each patient should be taken
into account before starting lipid-lowering therapy.
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